Open AccessAnti-interleukin-6 monoclonal antibody for cytokine storm in COVID-19
Author(s) -
Steven Douedi,
Moiuz Chaudhri,
Jeffrey A Miskoff
Publication year - 2020
Publication title -
annals of thoracic medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.639
H-Index - 33
eISSN - 1817-1737
pISSN - 1998-3557
DOI - 10.4103/atm.atm_286_20
Subject(s) - tocilizumab , medicine , cytokine storm , cytokine release syndrome , monoclonal antibody , covid-19 , immunology , pneumonia , cytokine , interleukin 6 , coronavirus , antibody , regimen , viral pneumonia , monoclonal , virology , disease , rheumatoid arthritis , infectious disease (medical specialty)
Novel coronavirus disease 2019 (COVID-19) is known to cause severe pneumonia and acute respiratory distress syndrome which may lead to death. Several treatments have been tested in the race to find a treatment regimen for this deadly viral infection. Tocilizumab, a recombinant humanized anti-interleukin-6 receptor monoclonal antibody, has been used and found to be beneficial in patients with COVID-19 and in cytokine storm. We present the case of a young, otherwise healthy male, presenting with COVID-19 and successfully treated in the intensive care unit with tocilizumab.